Poloxamers and poloxamines in nanoparticle engineering and experimental medicine

Trends in Biotechnology

Volumn 18, Issue 10, 2000, Pages 412-420

  Moghimi, S Moein ^a   Hunter, A Christy ^a  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; NANOPARTICLE; NONIONIC SURFACTANT; POLOXAMER; POLOXAMINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; CELL MEMBRANE; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMAGING; LYMPHATIC SYSTEM; MACROPHAGE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY; VASCULAR DISEASE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ARTIFICIAL ORGANS; BIOCOMPATIBLE MATERIALS; BIOMEDICAL ENGINEERING; CELL MEMBRANE; COMPLEMENT ACTIVATION; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; ETHYLENEDIAMINES; HUMANS; LYMPHOCYTES; PHAGOCYTOSIS; POLOXALENE; POLOXAMER; SPLEEN;

EID: 0034308222     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(00)01485-2     Document Type: Review

References (68)

1. 1 Storm, G. et al. (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug. Deliv. Rev. 16, 31-48
2. 2 Moghimi, S.M. et al. (1993) Coating particles with block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179, 157-165
3. 3 Li, J.T. and Caldwell, K. D. (1996) Plasma protein interactions with Pluronic treated colloids. Colloids Surfaces B-Biointerfaces 7, 9-22
4. 4 Li, J.T. et al. (1994) Surface properties of Pluronic polymeric colloids. Langmuir 10, 4475-4482
5. 5 Moghimi, S.M. et al. (1991) Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 177, 861-866
6. 6 Moghimi, S.M. (1997) Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo? Biochim. Biophys. Acta 1336, 1-6
7. 7 Carr, M.E. et al. (1996) Effects of poloxamer 407 on the assembly, structure and dissolution of fibrin clots. Blood Coagulation Fibrinol. 7, 109-113
8. 8 Moghimi, S.M. et al. (1994) Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional nodes. FEBS Lett. 344, 25-30
9. 9 Morikawa, K. et al. (1987) Enhancement of therapeutic effects of recombinant interleukin-2 on a transplantable rat fibrosarcoma by the use of a sustained release vehicle, Pluronic gel. Cancer 47, 37-41
10. 10 Fults, K.A. and Johnson, T.P. (1990) Sustained-release of urease from a poloxamer gel matrix. J. Patenter. Sci. Technol. 44, 58-65
11. 11 Katakam, M. et al. (1997) Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J. Control. Release 49, 21-26
12. 12 Schmolka, I.R. (1972) Artificial skin. I. Preparation and properties of PLURONIC® F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6, 571-582
13. 13 Nalbandian, R.M. et al. (1987) Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs. J. Biomed. Mater. Res. 21, 1135-1148
14. 14 Hunter, R.L. and Bennett, B. (1986) The adjuvant activity of nonionic block polymer surfactants III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23, 287-300
15. 15 Ke, Y. et al. (1997) Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Cell. Immunol. 176, 113-121
16. 16 Newman, M.J. et al. (1998) Design and development of adjuvant-active nonionic block copolymers. J. Pharm. Sci. 87, 1357-1362
17. 17 Hunter, R.L. et al. (1981) The adjuvant activity of nonionic block polymer surfactants I. The role of hydrophile-lipophile balance. J. Immunol. 127, 1244-1250
18. 18 Hunter, R.L. and Bennett, B. (1984) The adjuvant activity of nonionic block polymer surfactants II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133, 3167-3175
19. 19 Howerton, D.A. et al. (1990) Induction of macrophage Ia expression in vivo by synthetic block copolymer, L81. J. Immunol. 144, 1578-1584
20. 20 Ingram, D.A. et al. (1992) Phagocytic activation of human neutrophils by the detergent component of Fluosol. Am. J. Pathol. 140, 1081-1087
21. 21 Moghimi, S.M. and Murray, J.C. (1996) Poloxamer-188 revisited: a potentially valuable immune modulator? J. Natl. Cancer Inst. 88, 766-768
22. 22 Moghimi, S.M. and Gray, T. (1997) A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin. Sci. 93, 371-379
23. 23 Vercellotti, G.M. et al. (1982) Activation of plasma complement by perfluorocarbon artificial blood - probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 59, 1299-1304
24. 24 Szebeni, J. et al. (1998) Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90, 300-306
25. 25 Van Veen, H.W. and Konings, W.N. (1997) Multidrug transport from bacteria to man: similarities in structure and function. Semin. Cancer Biol. 8, 183-191
26. 26 Germann, U.A. et al. (1993) p-Glycoproteins: mediators of multidrug resistance. Semin. Cell Biol. 4, 63-76
27. 27 Schinkel, A.H. et al. (1994) Disruption of the mouse mdr-1 a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502
28. 28 Flens, M.J. et al. (1996) Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 148, 1237-1247
29. 29 Komarov, P.G. et al. (1996) Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid polyethylene glycol fatty acid diesters, novel inhibitors of P-glycoprotein function. Int. J. Cancer 68, 245-250
30. 30 Venne, A. et al. (1996) Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56, 3626-3629
31. 31 Miller, D.W. et al. (1997) Interactions of Pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjugate Chem. 8, 649-657
32. 32 Batrakova, E.V. et al. (1998) Effect of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm. Res. 15, 852-857
33. 33 Batrakova, E. V. et al. (1999) Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16, 1373-1379
34. 34 Jagannath, C. et al. (1999) Significantly improved oral uptake of amikacin in FVB mice in the presence of CRL-1605 copolymer. Life Sci. 64, 1733-1738
35. 35 Mayer, D.C. et al. (1994) Effects of poloxamer-188 in a rabbit model of hemorrhagic-shock. Ann. Clin. Lab. Sci. 24, 302-311
36. 36 Edwards, C.M. et al. (1998) Pluronic (R) F-68 inhibits agonistinduced platelet aggregation in human whole blood in vitro. Artif. Cells. Blood Substitutes Immobilization Biotechnol. 26, 441-447
37. 37 Kelly, R.F. et al. (1998) Effect of poloxamer 188 on collateral blood flow, myocardial infarct size, and left ventricular function in a canine model of prolonged (3-hour) coronary occlusion and reperfusion. J. Thromb. Thrombolysis 5, 239-247
38. 38 Maynard, C. et al. (1998) Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. Am. Heart J. 135, 797-804
39. 39 Toth, K. et al. (1997) The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction - (CORE trial substudy). Clin. Hemorheol. Microcirc. 17, 117-125
40. 40 Adams Greaves, P. et al. (1997) RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 90, 2041-2046
41. 41 Schaer, G.L. et al. (1996) Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction - results of a randomized, double-blind trail, placebo-controlled trail. Circulation 94, 298-307
42. 42 Follis, F. et al. (1996) Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. J. Invest. Surgery 9, 149-156
43. 43 SCRIP (2000) CytRx presses on with Flocor in sickle cell disease. Number 2526, March 29, p. 21
44. 44 Hannig, J. et al. (1999) Poloxamine 1107 sealing of radiopermeabilized erythrocyte membranes. Int. J. Radiat. Biol. 75, 379-385
45. 45 Lee, R.C. et al. (1999) Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries. Ann. New York Acad. Sci. 888, 266-273
46. 46 Schmolka, I.R. (1994) Physical basis for poloxamer interactions. Ann. New York Acad. Sci. 720, 92-97
47. 47 Bentley, P.K. et al. (1989) Purification of Pluronic F-68 for perfluorochemical emulsification. J. Pharm. Pharmacol. 41, 661-663
48. 48 Edwards, C.M. et al. (1999) Evaluation of commercial and purified PLURONIC® F-68 in a human blood neutrophil bioassay. Artif. Cells Blood Substitutes Immobilization Biotechnol. 27, 171-177
49. 49 Gardette, J.L. et al. (1999) Photooxidative degradation of polyether-based polymers. Macromol. Symp. 143, 95-109
50. 50 Costa, L. et al. (1992) Thermal and thermoxidative degradation of poly(ethylene oxide)-metal salt complexes. Macromolecules 25, 5512-5518
51. 51 (1982) Martindale: The Extra Pharmacopoeia (25th edn), (Reynolds, E.F., ed.), p. 1285, The Pharmaceutical Press
52. 52 Costa, L. et al. (1996) The thermal oxidation of poly(propylene oxide) and its complexes with LiBr and LiI. Polym. Degradation Stab. 53, 301-310
53. 53 The United States Pharmacopeia: The National Formulary (2000) United States Pharmacopeial Convention, Inc., Rockville, MD, USA, pp. 2492-2493
54. 54 (1996) BASF Performance Chemicals Catalogue, Pluronic® & Tetronic® Surfactants BASF Corporation, New Jersey, USA
55. 55 Porter, C.J.H. et al. (1992) Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow, Int. J. Pharm. 83, 273-276
56. 56 Emanuele, R.M. et al. (1997) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity. US Patent, Application Number 889342
57. 57 Wang, Z.J. and Stern, I.J. (1975) Disposition in rats of a polyoxypropylene-polyoxyethylene copolymer used in plasma fractionation. Drug Metab. Dispos. 3, 536-542
58. 58 Willcox, M.L. et al. (1978) A study of labelled Pluronic F-68 after intravenous injection into the dog. J. Swig. Res. 25, 349-356
59. 59 Rodgers, J.B. et al. (1984) Absorption and excretion of the hydrophobic surfactant, C-14 poloxalene 2930, in the rat. Drug Metab. Dispos. 12, 631-634
60. 60 Kawai, F. (1994) Biodegradation of polyethers and polyacrylate. In Biodegradable Plastics and Polymers (Doi, Y. and Fukuda, K., eds), pp. 24-38, Elsevier Science
61. 61 Jagannath, C. et al. (1995) Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. 39, 1349-1354
62. 62 Manowitz, N.R. et al. (1986) Dietary supplementation with Pluronic L-81 modifies hepatic secretion of very low density lipoproteins in the rat. J. Lipid Res. 26, 196-207
63. 63 Wiernik, P.H. et al. (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 47, 2486-2493
64. 64 Rowinsky, E.K. et al. (1993) Clinical toxicities encountered with Paclitaxel (TAXOL®). Semin. Oncol. 20, 1-15
65. 65 Groom, A.C. (1987) Microcirculation of the spleen: new concepts, new challenges. Microvasc. Res. 34, 269-289
66. 66 Weiss, L. and Tavassoli, M. (1970) Anatomical hazards to the passage of erythrocytes through the spleen. Semin. Hematol. 7, 372-380
67. 67 Moghimi, S.M. et al. (1993) An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim. Biophys. Acta 1157, 233-240
68. 68 Moghimi, S.M. et al. (1993) Effect of splenic congestion associated with haemolytic anaemia on filtration of'spleen-homing' microspheres. Clin. Sci. 84, 605-609